Shineco Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 3/6

Shineco şirketinin toplam hissedar öz sermayesi $36.6M ve toplam borcu $29.9M olup, bu da borç-öz sermaye oranını 81.6% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $84.2M ve $47.6M dir.

Anahtar bilgiler

81.6%

Borç/özkaynak oranı

US$29.86m

Borç

Faiz karşılama oranı	n/a
Nakit	US$406.11k
Eşitlik	US$36.58m
Toplam yükümlülükler	US$47.60m
Toplam varlıklar	US$84.18m

Son finansal sağlık güncellemeleri

Recent updates

Shineco CEO steps down, new CEO appointed

May 07

Shineco rallies on proposal to acquire 51% equity interests in Mayah Biological

May 04

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: SISI 'nin kısa vadeli varlıkları ( $20.9M ) kısa vadeli yükümlülüklerini ( $27.6M ) kapsamıyor.

Uzun Vadeli Yükümlülükler: SISI şirketinin kısa vadeli varlıkları ( $20.9M ) uzun vadeli yükümlülüklerini ( $20.0M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: SISI 'nin net borç/öz sermaye oranı ( 80.5% ) yüksek olarak değerlendiriliyor.

Borcun Azaltılması: SISI şirketinin borç/öz sermaye oranı son 5 yılda 3.3% seviyesinden 81.6% seviyesine yükseldi.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: SISI son raporlanan serbest nakit akışına göre 1 ay boyunca yeterli nakit pistine sahiptir, ancak o zamandan beri ek sermaye artırmıştır.

Tahmini Nakit Akışı: SISI serbest nakit akışı tahminlerine göre 1 ay boyunca yeterli nakit akışına sahip olması öngörülüyor, ancak o zamandan beri ek sermaye artırdı.

Shineco Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 3/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Shineco Receives Non-Compliance Notice Regarding Nasdaq Minimum Bid Requirement

Shineco Regains Compliance with Nasdaq Minimum Bid Price Requirement

Shineco Receives Deficiency Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Requirement Under Nasdaq Listing Rule 5550(a)(2)

Shineco Regains Compliance with Nasdaq Minimum Bid Price Requirement

Shineco Not Regains Compliance with the Nasdaq's Minimum Bid Price Requirement

Shineco Receives Deficiency Letter from Nasdaq

Recent updates

Full year 2024 earnings released: US$5.89 loss per share (vs US$5.43 loss in FY 2023)

Shineco, Inc., Annual General Meeting, Oct 21, 2024

Shineco Receives Non-Compliance Notice Regarding Nasdaq Minimum Bid Requirement

Shanchun Huang Engages in Discussions with Shineco

Shanchun Huang Engages in Discussions with Shineco

Shineco, Inc. has filed a Follow-on Equity Offering.

Shineco Regains Compliance with Nasdaq Minimum Bid Price Requirement

Shineco Receives Deficiency Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Requirement Under Nasdaq Listing Rule 5550(a)(2)

Shineco Regains Compliance with Nasdaq Minimum Bid Price Requirement

New major risk - Share price stability

New major risk - Financial position

Shineco, Inc., Annual General Meeting, Feb 01, 2024

Shineco, Inc. Announces the Appointment of Two New Executive Officers

New major risk - Share price stability

New major risk - Financial position

Full year 2023 earnings released: US$0.54 loss per share (vs US$2.60 loss in FY 2022)

Shineco Not Regains Compliance with the Nasdaq's Minimum Bid Price Requirement

Shineco, Inc.'S Subsidiary, Changzhou Biowin Pharmaceutical Co., Ltd., Receives Marketing Approval from China's Regulatory Body for Its Cardiac 5 Minute Test

New major risk - Market cap size

Shineco, Inc., Annual General Meeting, Jun 28, 2023

Third quarter 2023 earnings released: US$0.45 loss per share (vs US$0.30 loss in 3Q 2022)

Second quarter 2023 earnings released: US$0.15 loss per share (vs US$0.32 loss in 2Q 2022)

Shineco, Inc. (NasdaqCM:SISI) signed a letter of intent to acquire 80% stake in Dream Partner Limited for $40 million.

First quarter 2023 earnings released: US$0.17 loss per share (vs US$1.34 loss in 1Q 2022)

High number of new and inexperienced directors

Shineco Receives Deficiency Letter from Nasdaq

Full year 2022 earnings released: US$2.60 loss per share (vs US$4.73 loss in FY 2021)

Shineco, Inc. Appoints Aamir Ali Quraishi as Independent Director

Shineco, Inc. Resigns Yanzeng as Member of the Board of Directors

High number of new and inexperienced directors

Shineco, Inc. Announces Management Changes

Second quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Shineco, Inc. Appoints Qiyin Sun as Chief Medical Consultant

High number of new directors

Shineco, Inc. (NasdaqCM:SISI) entered into an agreement to acquire 51% stake in Xiang Peng You Kang (Beijing) Technology Co., Ltd.

Independent Director Harry Edelson has left the company

High number of new directors

Third quarter 2021 earnings released: US$2.36 loss per share (vs US$1.26 loss in 3Q 2020)

Shineco CEO steps down, new CEO appointed

Shineco, Inc. (NasdaqCM:TYHT) signed a non-binding terms of proposal to acquire a 51% stake in Mayah Biological Holdings Limited.

Shineco rallies on proposal to acquire 51% equity interests in Mayah Biological

Shineco, Inc. announced delayed 10-Q filing

New 90-day high: US$4.15

New 90-day high: US$3.82

New 90-day high: US$3.31

First quarter 2021 earnings released: US$0.35 loss per share

Full year earnings released - US$2.25 loss per share

New 90-day low - US$2.71

Shineco, Inc. Announces Management Changes

Shineco, Inc. (NasdaqCM:TYHT) signed a non-binding Letter of Intent to acquire 73.7% stake in Changzhou Biowin Pharmaceutical Co., Ltd from Beijing Kanghuayuan Technology Development Co., Ltd and Changzhou Kelinbo Venture Capital Partnership (limited partnership) for $25 million.

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin